2016-03-14T00:00:00.000-04:00
PANCRIT-1 trial,-0.370351
percent,-0.422278
clivatuzumab tetraxetan,-0.444881
disappointing survival data,-0.577848
metastatic pancreatic cancer,-0.444881
Street’s consensus,-0.478187
micro-cap renewable oils,-0.335491
bioproducts producer,-0.335491
patients,-0.444881
Monday,-0.474205
double digits,-0.419028
Phase,-0.370351
net loss,-0.33131
prior therapies,-0.444881
